Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. The RSVIG Study Group.

Infants with cardiopulmonary disease develop severe illness from respiratory syncytial virus (RSV) infection. Safety, feasibility, and pharmacokinetics of intravenous gamma globulin (IVIG) to prevent RSV illness were studied in 23 high-risk infants in a phase I trial. IVIG with an RSV neutralizing a...

Ausführliche Beschreibung

Bibliografische Detailangaben

Veröffentlicht in:	Antimicrob Agents Chemother
Hauptverfasser:	Groothuis, J R, Levin, M J, Rodriguez, W, Hall, C B, Long, C E, Kim, H W, Lauer, B A, Hemming, V G
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	American Society for Microbiology (ASM) 1991
Schlagworte:	Research Article
Online-Zugang:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC245192/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/1718213/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.35.7.1469
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!